Poly(2‐Hydroxyethyl Methacrylate) Hydrogel‐Based Microneedles for Metformin Release

The release of metformin, a drug used in the treatment of cancer and diabetes, from poly(2‐hydroxyethyl methacrylate), pHEMA, hydrogel‐based microneedle patches is demonstrated in vitro. Tuning the composition of the pHEMA hydrogels enables preparation of robust microneedle patches with mechanical p...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharma, Manoj B., Kap, Özlem, Abdelmohsen, Hend A. M., Ashton, Mark D., Harper, Garry R., Firlak, Melike, Aaltonen, Jasmine E., Bolland, Kerry A., Bragg, Ryan, Deeley, Sarah, Francis, Ella, Kazi, Nahin, Mapley, Bethany L., Oikonomou, Vasileios, Aljohani, Amal D., Cheneler, David, Kilic, Volkan, Horzum, Nesrin, Hardy, John G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10448145/
https://www.ncbi.nlm.nih.gov/pubmed/37635699
http://dx.doi.org/10.1002/gch2.202300002
Descripción
Sumario:The release of metformin, a drug used in the treatment of cancer and diabetes, from poly(2‐hydroxyethyl methacrylate), pHEMA, hydrogel‐based microneedle patches is demonstrated in vitro. Tuning the composition of the pHEMA hydrogels enables preparation of robust microneedle patches with mechanical properties such that they would penetrate skin (insertion force of a single microneedle to be ≈40 N). Swelling experiments conducted at 20, 35, and 60 °C show temperature‐dependent degrees of swelling and diffusion kinetics. Drug release from the pHEMA hydrogel‐based microneedles is fitted to various models (e.g., zero order, first order, second order). Such pHEMA microneedles have potential application for transdermal delivery of metformin for the treatment of aging, cancer, diabetes, etc.

Ejemplares similares